Maximus (NYSE:MMS – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $2.21 per share and revenue of $1.3275 billion for the quarter. Maximus has set its FY 2026 guidance at 8.250-8.550 EPS. Investors may review the information on the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:00 AM ET.
Maximus (NYSE:MMS – Get Free Report) last posted its earnings results on Thursday, May 7th. The health services provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Maximus had a net margin of 7.02% and a return on equity of 25.10%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the prior year, the company earned $2.01 EPS. The company’s revenue was down 4.1% on a year-over-year basis. On average, analysts expect Maximus to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Maximus Trading Up 3.2%
NYSE MMS opened at $62.16 on Tuesday. The firm has a market capitalization of $3.27 billion, a price-to-earnings ratio of 9.30 and a beta of 0.60. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.21 and a current ratio of 2.21. Maximus has a one year low of $52.73 and a one year high of $100.00. The company’s 50 day moving average price is $58.70 and its 200 day moving average price is $68.28.
Maximus Dividend Announcement
Institutional Trading of Maximus
Several large investors have recently bought and sold shares of MMS. EP Wealth Advisors LLC purchased a new stake in shares of Maximus during the fourth quarter valued at approximately $329,000. Empowered Funds LLC boosted its stake in shares of Maximus by 266.4% in the fourth quarter. Empowered Funds LLC now owns 9,544 shares of the health services provider’s stock valued at $824,000 after purchasing an additional 6,939 shares during the period. XTX Topco Ltd boosted its stake in shares of Maximus by 95.0% in the fourth quarter. XTX Topco Ltd now owns 15,595 shares of the health services provider’s stock valued at $1,346,000 after purchasing an additional 7,599 shares during the period. Voloridge Investment Management LLC grew its holdings in Maximus by 40.8% during the 4th quarter. Voloridge Investment Management LLC now owns 192,679 shares of the health services provider’s stock valued at $16,632,000 after purchasing an additional 55,872 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Maximus during the 4th quarter worth $1,714,000. Institutional investors and hedge funds own 97.21% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on MMS shares. Weiss Ratings downgraded shares of Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 20th. Zacks Research downgraded Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, Wall Street Zen raised Maximus from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has an average rating of “Hold”.
Check Out Our Latest Research Report on Maximus
Maximus Company Profile
Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.
Featured Stories
- Five stocks we like better than Maximus
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
